Breaking News
Get 50% Off 0
📈 Q2 Earnings Alert! Critical earnings dates you can't miss
See Calendar
Close

DBV Technologies (DBVT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow DBV Technologies's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.455 -0.320    -3.27%
25/07 - Closed. Currency in USD
After Hours
9.500
+0.045
+0.476%
21:46:20 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 60,968
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 9.405 - 10.415
DBV Technologies 9.455 -0.320 -3.27%

DBV Technologies Company Profile

 
Get an in-depth profile of DBV Technologies, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

106

Equity Type

ADR

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Contact Information

Address Bâtiment IRO 107 Av. de la République
Châtillon, 92320
France
Phone 33 1 55 42 78 78
Fax -

Top Executives

Name Age Since Title
Julie O'Neill 59 2017 Director
Paul-Henri Lambert 86 - Member of the Scientific Advisory Board
Ravi Madduri Rao 58 2021 Independent Director
Daniel B. Soland 69 2015 Independent Director
Michel de Rosen 74 2018 Independent Chairman of the Board
Jean-François Nicolas - 2019 Member of Scientific Advisory Board
Emma Guttman-Yassky - 2019 Member of Scientific Advisory Board
Hugh A. Sampson 76 2015 Scientific Adviser to the CEO & Chairman of Scientific Advisory Board
Miriam Merad - 2019 Member of Scientific Advisory Board
Betty A. Diamond - 2021 Member of Scientific Advisory Board
Mailys Ferrere 63 2012 Director
Timothy E. Morris 64 2021 Independent Director
Daniel Tassé 65 2018 CEO & Director
Adora Ndu 44 2021 Independent Director
Michael J. Goller 50 2015 Director
Jim Krueger - 2019 Member of Scientific Advisory Board
Daniele Guyot-Caparros 67 2022 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DBVT Comments

Write your thoughts about DBV Technologies
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email